The liver-selective NO donor, V-PYRRO/NO, protects against liver steatosis and improves postprandial glucose tolerance in mice fed high fat diet

Biochemical Pharmacology

Volumn 93, Issue 3, 2015, Pages 389-400

  Maslak, Edyta ^a   Zabielski, Piotr ^c   Kochan, Kamila ^a   Kus, Kamil ^a,b   Jasztal, Agnieszka ^a   Sitek, Barbara ^a   Proniewski, Bartosz ^a   Wojcik, Tomasz ^a   Gula, Katarzyna ^a   Kij, Agnieszka ^a   Walczak, Maria ^a,b   Baranska, Małgorzata ^a   Chabowski, Adrian ^c   Holland, Ryan J ^d   Saavedra, Joseph E ^e   Keefer, Larry K ^d   Chlopicki, Stefan ^a,b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d NATIONAL CANCER INSTITUTE   (United States)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

Fatty acid metabolism; Glucose tolerance; Hepatoprotection; Liver steatosis; Nitric oxide

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; METFORMIN; NITRIC OXIDE DONOR; O 2 VINYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUN 1,2 DIOLATE; GLUCOSE BLOOD LEVEL; O(2)-VINYL-1-(PYRROLIDIN-1-YL)DIAZEN-1-IUM-1,2-DIOLATE; PROTECTIVE AGENT; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIOGENESIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG MECHANISM; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY LIVER; GLUCOSE TOLERANCE; LIPID COMPOSITION; LIPID DIET; LIVER MITOCHONDRION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; METABOLISM; PHYSIOLOGY; POSTPRANDIAL STATE; PROCEDURES;

ANIMALS; BLOOD GLUCOSE; DIET, HIGH-FAT; FATTY LIVER; GLUCOSE TOLERANCE TEST; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE DONORS; POSTPRANDIAL PERIOD; PROTECTIVE AGENTS; PYRROLIDINES;

EID: 84921869378     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.12.004     Document Type: Article

References (57)

1. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
2. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011;332:1519-23.
3. Mantena SK, Vaughn DP, Andringa KK, Eccleston HB, King AL, Abrams Ga. et al. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J 2009;417:183-93.
4. Ijaz S, Yang W, Winslet MC, Seifalian AM. Impairment of hepatic microcirculation in fatty liver. Microcirculation 2003;10:447-56.
5. Haukeland JW, Konopski Z, Eggesbø HB, von Volkmann HL, Raschpichler G, Bjøro K, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009;44:853-60.
6. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307.
7. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659-68.
8. Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007;47:135-41.
9. Zhang X, Li Z-Z, Liu D-F, Xu X, Mei Z-C, Shen W. Angiotensin-converting enzyme inhibitors improve hepatic steatosis by modulating expression of tumour necrosis factor-alpha, interleukin-6 and adiponectin receptor-2 in rats with type 2 diabetes. Clin Exp Pharmacol Physiol 2009;36:631-6.
10. Paschos P, Tziomalos K. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol 2012;4:327-31.
11. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001;104:342-5.
12. Jobgen WS, Fried SK, Fu WJ, Meininger CJ, Wu G. Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J Nutr Biochem 2006;17:571-88.
13. Fu WJ, Haynes TE, Kohli R, Hu J, Shi W, Spencer TE, et al. Dietary L arginine supplementation reduces fat mass in zucker diabetic fatty rats. J Nutr 2005;714-21.
14. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 2003;299:896-9.
15. García-Villafranca J, Guillén A, Castro J. Involvement of nitric oxide/cyclic GMP signaling pathway in the regulation of fatty acid metabolism in rat hepatocytes. Biochem Pharmacol 2003;65:807-12.
16. Nisoli E, Falcone S, Tonello C, Cozzi V, Palomba L, Fiorani M, et al. Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. Proc Natl Acad Sci USA 2004;101:16507-12.
17. Ijaz S, Yang W, Winslet MC, Seifalian AM. The role of nitric oxide in the modulation of hepatic microcirculation and tissue oxygenation in an experimental model of hepatic steatosis. Microvasc Res 2005;70:129-36.
18. Saavedra JE, Billiar TR, Williams DL, Kim Y, Watkins SC, Keefer LK. Targeting Nitric Oxide (NO) Delivery in Vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-r-induced apoptosis and toxicity in the liver. J Med Chem 1997;2623:1947-54.
19. Inami K, Nims RW, Srinivasan A, Citro ML, Saavedra JE, Cederbaum AI, et al. Metabolism of a liver-selective nitric oxide-releasing agent, V-PYRRO/NO, by human microsomal cytochromes P450. Nitric Oxide 2006;14:309-15.
20. Ricciardi R, Foley DP, Quarfordt SH, Saavedra JE, Keefer LK, Wheeler SM, et al. V-PYRRO/NO: an hepato-selective nitric oxide donor improves porcine liver hemodynamics and function after ischemia reperfusion. Transplantation 2001;71:193-8.
21. Moal F, Veal N, Vuillemin E, Barrière E, Wang J, Fizanne L, et al. Hemodynamic and anti fi brotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats. World J Gastroenterol 2006;12:6639-45.
22. Kim YM, Kim TH, Chung HT, Talanian RV, Yin XM, Billiar TR. Nitric oxide prevents tumor necrosis factor alpha-induced rat hepatocyte apoptosis by the interruption of mitochondrial apoptotic signaling through S-nitrosylation of caspase-8. Hepatology 2000;32:770-8.
23. Liu J, Qu W, Saavedra JE, Waalkes MP. The Nitric Oxide Donor, O 2 -Vinyl 1-(Pyrrolidin-1-yl) diazen-1-ium-1, 2-diolate (V-PYRRO/NO), protects against cadmium-induced hepatotoxicity in mice. J Pharmacol Exp Ther 2004;310:18-24.
24. Liu J, Li C, Waalkes MP, Clark J, Myers P, Saavedra JE, et al. The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced hepatotoxicity in mice. Hepatology 2003;37:324-33.
25. Stinson SF, House T, Bramhall C, Saavedra JE, Keefer LK, Nims RW. Plasma pharmacokinetics of a liver-selective nitric oxide-donating diazeniumdiolate in the male C57BL/6 mouse. Xenobiotica 2002;32:339-47.
26. Cacho J, Sevillano J, Castro J De, Herrera E, Ramos MP. Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague- Dawley rats. Am J Physiol Endocrinol Metab 2008;295:1269-76.
27. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004;165:1499-508.
28. Baranowski M, Zabielski P, Harasim E, Harasiuk D, Chabowski A, Gorski J. Liver X receptor agonist T0901317 enhanced peroxisome proliferator-activated receptor-delta expression and fatty acid oxidation in rat skeletal muscle. J Physiol Pharmacol 2013;64:289-97.
29. Zabielski P, Baranowski M, Błachnio-Zabielska A, Zendzian-Piotrowska M, Górski J. The effect of high-fat diet on the sphingolipid pathway of signal transduction in regenerating rat liver. Prostaglandins Other Lipid Mediat 2010;93:75-83.
30. Wierzbicki M, Chabowski A, Zendzian-Piotrowska M, Harasim E, Górski J. Chronic, in vivo, PPARalpha activation prevents lipid overload in rat liver induced by high fat feeding. Adv Med Sci 2009;54:59-65.
31. Kochan K, Marzec KM, Lipska K, Jasztal A, Maslak E, Musiolik H, et al. Pathological changes in biochemical profile of liver in atherosclerosis and diabetes assessed by Raman spectroscopy. Analyst 2013;3885-90.
32. Hedli CC, Hoffmann MJ, Ji S, Thomas PE, Snyder R. Benzene metabolism in the isolated perfused mouse liver. Toxicol Appl Pharmacol 1997;146:60-8.
33. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci 2012;122:253-70.
34. Bess E, Fisslthaler B, Frömel T, Fleming I. Nitric oxide-induced activation of the AMP-activated protein kinase (2 subunit attenuates I(B kinase activity and inflammatory responses in endothelial cells. PLoS One 2011;6:e20848.
35. Davis BJ, Xie Z, Viollet B, Zou M. Drug metformin stimulates nitric oxide synthesis in vivo and endothelial nitric oxide synthase. Diabetes 2006;55:496-505.
36. Kim Y-W, Park S-Y, Kim J-Y, Huh J-Y, Jeon W-S, Yoon C-J, et al. Metformin restores the penile expression of nitric oxide synthase in high-fat-fed obese rats. J Androl 2007;28:555-60.
37. Fisslthaler B, Fleming I, Keserü B, Walsh K, Busse R. Fluid shear stress and NO decrease the activity of the hydroxy-methylglutaryl coenzyme A reductase in endothelial cells via the AMP-activated protein kinase and FoxO1. Circ Res 2007;100:e12-21.
38. Soltys CM, Kovacic S, Dyck JRB, Jason RB, Wallimann T, Carling D, et al. Activation of cardiac AMP-activated protein kinase by LKB1 expression or chemical hypoxia is blunted by increased Akt activity. Am J Physiol Hear Circ Physiol 2006;290:2472-9.
39. Wang XL, Zhang L, Youker K, Zhang M-X, Wang J, LeMaire Sa. et al. Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase. Diabetes 2006;55:2301-10.
40. Xiao-Yun X, Zhuo-Xiong C, Min-Xiang L, Xingxuan H, Schuchman EH, Feng L, et al. Ceramide mediates inhibition of the AKT/eNOS signaling pathway by palmitate in human vascular endothelial cells. Med Sci Monit 2009;15:BR254-61.
41. Kamath S, Chavez AO, Gastaldelli A, Casiraghi F, Halff GA, Abrahamian GA, et al. Coordinated defects in hepatic long chain fatty acid metabolism and triglyceride accumulation contribute to insulin resistance in non-human primates. PLoS One 2011;6:e27617.
42. Konstantynowicz K, Mikłosz A, Stepek T, Chabowski A. The role of hepatic lipid accumulation in the development of insulin resistance in the liver. Postep Hig Med Dosw 2011;65:236-43.
43. Chavez AO, Lopez-Alvarenga JC, Tejero ME, Triplitt C, Bastarrachea RA, Sriwijitkamol A, et al. Physiological and molecular determinants of insulin action in the baboon. Diabetes 2008;57:899-908.
44. Smukler SR, Tang L, Wheeler MB, Salapatek AMF. Exogenous nitric oxide and endogenous glucose-stimulated beta-cell nitric oxide augment insulin release. Diabetes 2002;51:3450-60.
45. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-61.
46. Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-69.
47. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, et al. Mechanism by which metformin reduces glucose production in Type 2 diabetes. Diabetes 2000;49:2063-9.
48. Deleve LD, Wang X, Kanel GC, Ito Y, Bethea NW, Mccuskey MK, et al. Decreased hepatic nitric oxide production contributes. Hepatology 2003;38:900-8.
49. Bauer C, Walcher F, Kalweit U. Role of nitric oxide in the regulation of the hepatic microcirculation in viva. J Heparology 1997;27:1089-95.
50. Kakumitsu S, Shijo H, Yokoyama M, Kim T, Akiyoshi N, Ota K, et al. Effects of L-arginine on the systemic, mesenteric, and hepatic circulation in patients with cirrhosis. Hepatology 1998;27:377-82.
51. Gustafsson BI, Wallin M, Delbro DS, Friman S. Nitric oxide-mediated effects on liver blood flow. Transplant Proc 2005;37:3338-9.
52. Takayama F, Egashira T, Kawasaki H, Mankura M, Nakamoto K, Okada S, et al. A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): hypoxemia enhances the development of NASH. J Clin Biochem Nutr 2009;45:335-40.
53. Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, et al. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol 2008;48:300-7.
54. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, et al. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004;106:635-43.
55. Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med 2004;37:1499-507.
56. Sigruener A, Kleber ME, Heimerl S, Liebisch G, Schmitz G, Maerz W. Glycerophospholipid and sphingolipid species and mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. PLoS One 2014;9:e85724.
57. Yin W, Carballo-Jane E, McLaren DG, Mendoza VH, Gagen K, Geoghagen NS, et al. Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res 2012;53:51-65.